Visiopharm Overview

  • Founded

  • 2001

Founded
  • Status

  • Private

  • Employees

  • 121

Employees
  • Latest Deal Type

  • Later Stage VC

  • Investors

  • 6

Visiopharm General Information

Description

Developer of pioneering image analysis and precision pathology tools designed to support researchers, diagnostics, drug development, and the development of companion diagnostics. The company's tools use artificial intelligence and deep learning to deliver tissue data mining, precision results, standardization of tissue data, and improved productivity, enabling medical practitioners to operate on a wide variety of virtual slide microscopes.

Contact Information

Website
www.visiopharm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • Agern Allé 24
  • 2970 Horsholm
  • Denmark
+45 88 00 00 00

Visiopharm Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visiopharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 01-Sep-2020 000.00 Completed Generating Revenue
2. Later Stage VC 23-Aug-2018 000.00 000.00 Completed Generating Revenue
1. Later Stage VC 05-Oct-2007 Completed Generating Revenue
To view Visiopharm’s complete valuation and funding history, request access »

Visiopharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pioneering image analysis and precision pathology tools designed to support researchers, diagnostics, drug
Decision/Risk Analysis
Horsholm, Denmark
121 As of 2022
000.00
0000000000 0 000.00

000000

ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dol
0000000000000 00000000
Boston, MA
000 As of 0000
00000
0.000 0000-00-00
00000000000 00000

0000 0

ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
00000 0000000000 0000000000 0000000
Tel Aviv, Israel
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visiopharm Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PathAI Venture Capital-Backed Boston, MA 000 00000 00000000000 00000
0000 0000000 00000 Venture Capital-Backed Tel Aviv, Israel 00 000.00 00000000000 000.00
0000000 Formerly VC-backed Helsinki, Finland 00 000.00 00000000 000.00
000000 0000 Angel-Backed NM 00 000000000
To view Visiopharm’s complete competitors history, request access »

Visiopharm Patents

  • 24

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Visiopharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3757872-A1 Scanning/pre-scanning quality control of slides Withdrawn 28-Jun-2019 00000000000 0
US-20210150701-A1 Method for training a deep learning model to obtain histopathological information from images Pending 15-Jun-2017 00000000000
EP-3639191-A1 Method for training a deep learning model to obtain histopathological information from images Granted 15-Jun-2017 00000000000
EP-3639191-B1 Method for training a deep learning model to obtain histopathological information from images Active 15-Jun-2017 0000000000
US-20170212018-A1 Assessment of staining quality Granted 10-Mar-2014 G01N1/30
To view Visiopharm’s complete patent history, request access »

Visiopharm Executive Team (13)

Name Title Board Seat Contact Info
Michael Grunkin Ph.D Co-Founder, Chief Executive Officer & Board Member
Kristian Dalhof Nielsen Chief Financial Officer
Christian Kaltoft Chief Operating Officer
Johan Hansen Co-Founder, Chief Technical Officer & Board Member
Amanda Lowe Managing Director, Americas
You’re viewing 5 of 13 executive team members. Get the full list »

Visiopharm Board Members (10)

Name Representing Role Since
Claus Møller MD The ATP Group Board Member 000 0000
Henrik Stender Ph.D Self Board Member 000 0000
Jeannett Hvidkjær Visiopharm Board Member 000 0000
Johan Hansen Visiopharm Co-Founder, Chief Technical Officer & Board Member 000 0000
Martin Bonde Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Visiopharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visiopharm Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BankInvest Group Asset Manager Minority 000 0000 000000 0
C. L. David Foundation and Collection Limited Partner Minority 000 0000 000000 0
The ATP Group Limited Partner Minority 000 0000 000000 0
The Growth Fund PE/Buyout Minority 000 0000 000000 0
Vækstfonden Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Visiopharm Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 0000000 01-Dec-2016 0000000000 Other Devices and Supplies 0000000 0
Digital Pathology Consultants 08-Dec-2012 Merger/Acquisition Consulting Services (B2B) 0000000 0
To view Visiopharm’s complete acquisitions history, request access »

Ready to get started?

Request a free trial